SCHEMBL6478952

SCHEMBL6478952

COc1cc(Nc2ncnc(-n3c(Cl)nc4ccccc43)n2)cc(OC)c1OC

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 6/20 0.74
LCK P06239 4/20 0.74
MAPK14 Q16539 2/20 0.74
IGF1R P08069 3/20 0.57
EPHB4 P54760 2/20 0.55
AURKB Q96GD4 2/20 0.50
PTK2 Q05397 7/20 0.49
FGFR1 P11362 2/20 0.48
MET P08581 2/20 0.48
AURKA O14965 1/20 0.48
DAPK3 O43293 1/20 0.48
JAK2 O60674 1/20 0.48
PRKD3 O94806 1/20 0.48
MAP4K4 O95819 1/20 0.48
PAK4 O96013 1/20 0.48
ABL1 P00519 1/20 0.48
NTRK1 P04629 1/20 0.48
FYN P06241 1/20 0.48
CSF1R P07333 1/20 0.48
RET P07949 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6492567 0.89 LCK (0.60) KDRLCKMAPK14IGF1REPHB4
SCHEMBL6488628 0.88 LCK (0.58) KDRLCKMAPK14IGF1REPHB4
SCHEMBL6479597 0.86 KDR (0.57) KDRLCKMAPK14IGF1REPHB4
SCHEMBL14214730 0.84 KDR (0.82) KDRLCKMAPK14IGF1REPHB4
SCHEMBL6493240 0.83 KDR (0.56) KDRLCKMAPK14IGF1REPHB4
SCHEMBL6479352 0.83 KDR (0.54) KDRLCKMAPK14IGF1REPHB4
SCHEMBL14214609 0.83 KDR (0.87) KDRLCKMAPK14IGF1REPHB4
SCHEMBL14214612 0.83 KDR (0.82) KDRLCKMAPK14IGF1REPHB4
SCHEMBL14214680 0.82 LCK (0.76) KDRLCKMAPK14IGF1RPTK2
SCHEMBL14214615 0.82 KDR (0.85) KDRLCKMAPK14IGF1REPHB4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6864255-B2 Substituted triazinyl amide derivatives and methods of use AMGEN INC. (US) 2005-03-08 US disclosed
EP-1385833-A1 TRIAZINYL AMIDE DERIVATIVES AS ANGIOGENESIS INHIBITORS Amgen Inc. (US) 2004-02-04 EP disclosed
US-20030087908-A1 Substituted triazinyl amide derivatives and methods of use AMGEN INC. 2003-05-08 US disclosed
WO-2002083654-A1 TRIAZINYL AMIDE DERIVATIVES AS ANGIOGENESIS INHIBITORS AMGEN INC. (US) 2002-10-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030087908-A1 Substituted triazinyl amide derivatives and methods of use FLT4, FLT1, VEGFA KDR 4/4885LCK 1859/4885MAPK14 3556/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.